Aptus Pharma Limited (BOM:544529)

Market Cap	5.10B
Revenue (ttm)	465.75M +160.8%
Net Income	46.20M +437.3%
EPS	3.11 +35.7%
Shares Out	17.15M
PE Ratio	95.50
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,600
Open	290.00
Previous Close	295.50
Day's Range	282.25 - 310.25
52-Week Range	32.32 - 310.25
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Aptus Pharma

Aptus Pharma Limited engages in the marketing and distribution of finished pharmaceutical formulations. The company operates through four divisions: Aptus Pharma, Pioneer division which includes marketing of acute therapies including general anti-infectives, pain management, antacids, and gastrointestinal drugs; Aptus CD Care, Cardiac Diabetic division which includes marketing of chronic therapies, including anti-hypertensive, anti-diabetic, and lipid-lowering; Aptus Wellcare offers wellness and nutraceutical products, over-the-counter (OTC) fo...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2010
• Country: India
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544529

Financial Performance

In fiscal year 2026, Aptus Pharma's revenue was 465.75 million, an increase of 89.65% compared to the previous year's 245.58 million. Earnings were 46.20 million, an increase of 49.05%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 5, 2026

Data Sources Report a data error